Filter by: patients
Home > Community Treatment Reports and Side Effects > Brovana Treatment Report
What is Brovana?

Brovana is a brand name for the drug arformoterol. It is administered in a nebulized preparation and used for long-term maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
COPD (Chronic Obstructive Pulmonary Disease) 2 0
Shortness of breath (dyspnea) 1 1 Efficacy_slight

See 1 patient currently taking Brovana

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 0
Mild
 0
None
 1

Reported Dosages

  2 x 15 mcg/2 mL daily
  1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Brovana (multiple reasons could be selected)
Reason # Patients Percentage of patients
Did not seem to work 1   Did not seem to work: 50%
Doctor's advice 1   Doctor's advice: 50%
Side effects too severe 1   Side effects too severe: 50%

See all 2 patients who’ve stopped taking Brovana

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Brovana

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0
0

Stopped Taking Brovana

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Brovana

Always
 0 0%
Usually
 1 100%
Sometimes
 0 0%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Brovana

Very
 0 0%
Somewhat
 1 100%
A little
 0 0%
Not at all
 0 0%

Cost

Paid out of pocket

Cost of Brovana

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 1 100%
< $25
 0 0%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 27, 2012.